Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study
Cancer · 2024
DOI: 10.1002/cncr.35323 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, 2024. Verfasst von Francesco Schettini und 44 weiteren Autor:innen. Beteiligte Einrichtung: Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Germ-Line Mutation, Erb-b2 Receptor Tyrosine Kinases, Internationality. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Background
Breast cancer (BC) in women aged ≤40 years carrying germline pathogenetic variants (PVs) in BRCA1/2 genes is infrequent but often associated with aggressive features. Human epidermal growth factor receptor 2 (HER2)‐low‐expressing BC has recently emerged as a novel therapeutic target but has not been characterized in this rare patient subset.
Methods
Women aged ≤40 years with newly diagnosed early‐stage HER2‐negative BC (HER2‐0 and HER2‐low) and germline BRCA1/2 PVs from 78 health care centers worldwide were retrospectively included. Chi‐square test and Student t ‐test were used to describe variable distribution between HER2‐0 and HER2‐low. Associations with HER2‐low status were assessed with logistic regression. Kaplan–Meier method and Cox regression analysis were used to assess disease‐free survival (DFS) and overall survival. Statistical significance was considered for p ≤ .05.
Results
Of 3547 included patients, 32.3% had HER2‐low BC, representing 46.3% of hormone receptor–positive and 21.3% of triple‐negative (TN) tumors. HER2‐low vs. HER2‐0 BC were more often of grade 1/2 ( p < .001), hormone receptor–positive ( p < .001), and node‐positive ( p = .003). BRCA2 PVs were more often associated with HER2‐low than BRCA1 PVs ( p < .001). HER2‐low versus HER2‐0 showed better DFS (hazard ratio [HR], 0.86; 95% CI, 0.76–0.97) in the overall population and more favorable DFS (HR, 0.78; 95% CI, 0.64–0.95) and overall survival (HR, 0.65; 95% CI, 0.46–0.93) in the TN subgroup. Luminal A–like tumors in HER2‐low ( p = .014) and TN and luminal A‐like in HER2‐0 ( p = .019) showed the worst DFS.
Conclusions
In young patients with HER2‐negative BC and germline BRCA1/2 PVs, HER2‐low disease was less frequent than expected and more frequently linked to BRCA2 PVs and associated with luminal‐like disease. HER2‐low status was associated with a modestly improved prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.
- Department of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
- U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.
- Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
ORCID-Profile: Francesco Schettini, Antonio Di Meglio, Katarzyna Pogoda, Elisa Agostinetto, Nerea Lopetegui-Lia, Angela Toss, Marion Acheritogaray, Stephanie M Wong, Cynthia Villarreal-Garza, Laura De Marchis, Leonor Vasconcelos de Matos, Yara Abdou, Alfonso Cortés Salgado, Giuseppe Curigliano, Aleix Prat, Matteo Lambertini
Förderung
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Schettini, F., Blondeaux, E., Molinelli, C., Bas, R., Kim, H. J., Di Meglio, A., Bernstein Molho, R., Linn, S. C., Pogoda, K., Carrasco, E., Punie, K., Agostinetto, E., Lopetegui-Lia, N., Phillips, K. A., Toss, A., Rousset-Jablonski, C., Acheritogaray, M., Ferrari, A., Paluch-Shimon, S., …, & Lambertini, M. (2024). Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer. https://doi.org/10.1002/cncr.35323
Vancouver
Schettini F, Blondeaux E, Molinelli C, Bas R, Kim HJ, Di Meglio A, et al. Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer. 2024. doi:10.1002/cncr.35323
BibTeX
@article{Schettini2024,
author = {Schettini, Francesco and Blondeaux, Eva and Molinelli, Chiara and Bas, Raphaëlle and Kim, Hee Jeong and Di Meglio, Antonio and Bernstein Molho, Rinat and Linn, Sabine C and Pogoda, Katarzyna and Carrasco, Estela and Punie, Kevin and Agostinetto, Elisa and Lopetegui-Lia, Nerea and Phillips, Kelly-Anne and Toss, Angela and Rousset-Jablonski, Christine and Acheritogaray, Marion and Ferrari, Alberta and Paluch-Shimon, Shani and Fruscio, Robert and Cui, Wanda and Wong, Stephanie M and Vernieri, Claudio and Dieci, Maria Vittoria and Matikas, Alexios and Rozenblit, Mariya and Villarreal-Garza, Cynthia and De Marchis, Laura and Puglisi, Fabio and Vasconcelos de Matos, Leonor and Mariño, Monica and Teixeira, Luis and Graffeo, Rossella and Rognone, Alessia and Chirco, Alessandra and Antone, Nicoleta and Abdou, Yara and Marhold, Maximilian and Božović-Spasojević, Ivana and Cortés Salgado, Alfonso and Carmisciano, Luca and Bruzzone, Marco and Curigliano, Giuseppe and Prat, Aleix and Lambertini, Matteo},
title = {Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35323}
}
EUVIMED